Dynavax Technologies Corporation ( NASDAQ: DVAX) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - ...
"I am pleased to be joining Terns as we advance our lead oncology and obesity programs towards important clinical readouts ...
SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its fourth quarter and full year 2024 financial results and provided a corporate update.
Interesting Engineering on MSN6h
New mRNA vaccine shows promise against pancreatic cancer, may extend life by 10 yearsIn a significant development for pancreatic cancer treatment, a phase 1 clinical trial has highlighted the potential of personalized mRNA vaccines to treat the deadly disease. This research comes at a ...
BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...
Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...
The FARE Innovation Award Diagnostic Challenge is made possible through generous support from the Naddisy Foundation, the ...
The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for ...
Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback